{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:25:20Z","timestamp":1767918320466,"version":"3.49.0"},"reference-count":170,"publisher":"Elsevier","isbn-type":[{"value":"9780323993999","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007320","name":"Albert Einstein Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.ircmb.2022.04.003","type":"book-chapter","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T17:28:41Z","timestamp":1653326921000},"page":"163-192","source":"Crossref","is-referenced-by-count":7,"title":["Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2022.04.003_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/nri1248","article-title":"CD28-mediated co-stimulation: a quantitative support for TCR signalling","volume":"3","author":"Acuto","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0015","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-06-2399","article-title":"IL-2 administration increases CD4+CD25hi Foxp3 + regulatory T cells in cancer patients","volume":"107","author":"Ahmadzadeh","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2017.10.009","article-title":"CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness","volume":"47","author":"Ahrends","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13438-1","article-title":"CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities","volume":"10","author":"Ahrends","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-0973-y","article-title":"A short CD3\/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy","volume":"14","author":"Alvarez-Fern\u00e1ndez","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2011.10.019","article-title":"Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer","volume":"20","author":"Anders","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0040","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-11-2614","article-title":"Dissection of T-cell antigen specificity in human melanoma","volume":"72","author":"Andersen","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0045","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated il2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0050","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-17-0467","article-title":"T-cell responses in the microenvironment of primary renal cell carcinoma-implications for adoptive cell therapy","volume":"6","author":"Andersen","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0055","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20031111","article-title":"Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation","volume":"199","author":"Arens","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/mt.2015.71","article-title":"Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma","volume":"23","author":"Beane","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0070","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16003","article-title":"Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma","volume":"8","author":"Bjoern","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0080","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00286-10","article-title":"Translating tumor antigens into cancer vaccines","volume":"18","author":"Buonaguro","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08304-z","article-title":"Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients","volume":"10","author":"Cafri","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0090","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.03.6830","article-title":"Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma","volume":"24","author":"Cesana","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0100","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1040219","article-title":"Triggering co-stimulation directly in melanoma tumor fragments drives CD8+ tumor-infiltrating lymphocyte expansion with improved effector-memory properties","volume":"4","author":"Chacon","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0105","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-1934","article-title":"Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy","volume":"21","author":"Chacon","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0110","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1113748109","article-title":"Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype","volume":"109","author":"Chapuis","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0115","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-13-0087","article-title":"Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I","volume":"2","author":"Chapuis","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0125","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.94.5.1914","article-title":"A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening","volume":"94","author":"Chen","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/ng.2762","article-title":"Emerging landscape of oncogenic signatures across human cancers","volume":"45","author":"Ciriello","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0358-2","article-title":"Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model","volume":"6","author":"Contreras","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0145","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1901172","article-title":"Cutting edge: antitumor immunity by pathogen-specific CD8 T cells in the absence of cognate antigen recognition","volume":"204","author":"Danahy","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(64)90126-6","article-title":"Treatment of primary fibrosarcoma in the rat with immune lymphocytes","volume":"284","author":"Delorme","year":"1964","journal-title":"The Lancet"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-3083.2011.02640.x","article-title":"Characterization and comparison of \u201cstandard\u201d and \u201cyoung\u201d tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution","volume":"75","author":"Donia","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0160","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-1692","article-title":"PD-1\u00fe polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocyte therapy for cancer","volume":"23","author":"Donia","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0165","doi-asserted-by":"crossref","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0170","doi-asserted-by":"crossref","DOI":"10.1097\/00002371-200205000-00007","article-title":"A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma","volume":"25","author":"Dudley","year":"2002","journal-title":"J. Immunother."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0180","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-10-1297","article-title":"CD8+ enriched \u201cYoung\u201d tumor infiltrating lymphocytes can mediate regression of metastatic melanoma","volume":"16","author":"Dudley","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.10.006","article-title":"Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8+ T cells","volume":"36","author":"Etxeberria","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0195","article-title":"Immunotherapy and chemotherapy of moloney sarcoma virus-induced tumors in mice","volume":"29","author":"Fefer","year":"1969","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0200","doi-asserted-by":"crossref","DOI":"10.1126\/science.1152586","article-title":"Clonal integration of a polyomavirus in human Merkel cell carcinoma","volume":"319","author":"Feng","year":"2008","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0205","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1158\/0008-5472.CAN-17-0236","article-title":"Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy","volume":"77","author":"Fernandez-Poma","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0210","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-2824","article-title":"Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions","volume":"21","author":"Filatenkov","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0215","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-17-3649","article-title":"Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome","volume":"24","author":"Forget","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0220","doi-asserted-by":"crossref","DOI":"10.1097\/00002371-199410000-00004","article-title":"Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial","volume":"16","author":"Freedman","year":"1994","journal-title":"J. Immunother."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-60738-4","article-title":"CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer","volume":"10","author":"Friese","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0230","article-title":"Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes","volume":"1","author":"Fujita","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-021-00197-6","article-title":"A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types","volume":"2","author":"Gartner","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0240","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0245","doi-asserted-by":"crossref","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0250","doi-asserted-by":"crossref","DOI":"10.1038\/nm.1982","article-title":"Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells","volume":"15","author":"Gattinoni","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0255","doi-asserted-by":"crossref","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0260","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0265","doi-asserted-by":"crossref","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0270","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0275","doi-asserted-by":"crossref","DOI":"10.1172\/JCI127967","article-title":"Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes","volume":"129","author":"Gros","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0280","article-title":"Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line","volume":"3","author":"Gross","year":"1943","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0285","doi-asserted-by":"crossref","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0290","doi-asserted-by":"crossref","DOI":"10.1172\/JCI80008","article-title":"Tumor neoantigens: building a framework for personalized cancer immunotherapy","volume":"125","author":"Gubin","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005177","article-title":"CD39 expression identifies terminally exhausted CD8+ T cells","volume":"11","author":"Gupta","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0300","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2007.0171","article-title":"Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2","volume":"19","author":"Heemskerk","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0305","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20030916","article-title":"CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool","volume":"198","author":"Hendriks","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0310","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0315","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-09-113050","article-title":"IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy","volume":"111","author":"Hinrichs","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0325","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.172.10.6057","article-title":"T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product","volume":"172","author":"Huang","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0335","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1","volume":"358","author":"Hunder","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0340","article-title":"Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model","volume":"7","author":"Idorn","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0345","doi-asserted-by":"crossref","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0350","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0b013e318209c94c","article-title":"Establishment and large-scale expansion of minimally cultured young tumor infiltrating lymphocytes for adoptive transfer therapy","volume":"34","author":"Itzhaki","year":"2011","journal-title":"J. Immunother."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0355","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","article-title":"Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma","volume":"37","author":"Jazaeri","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0360","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.5463","article-title":"A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0365","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0256-z","article-title":"Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice","volume":"5","author":"Jing","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0370","article-title":"Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes","volume":"146","author":"Kansas","year":"1991","journal-title":"J. Immunol. (Balt. Md. 1950)"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0375","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0380","doi-asserted-by":"crossref","DOI":"10.1089\/10430340260355374","article-title":"Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2","volume":"13","author":"Kershaw","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0385","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0390","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-20-0270","article-title":"CD39 identifies the CD4\u00fe tumor-specific T-cell population in human cancer","volume":"8","author":"Kortekaas","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0395","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-09-4446","article-title":"Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation","volume":"70","author":"Kozin","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0400","doi-asserted-by":"crossref","DOI":"10.1007\/BF00199837","article-title":"Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer","volume":"24","author":"Kradin","year":"1987","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(89)91609-7","article-title":"Tumour-infiltrating lymphocytes and INTERLEUKIN-2 in treatment of advanced cancer","volume":"333","author":"Kradin","year":"1989","journal-title":"The Lancet"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0410","doi-asserted-by":"crossref","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0420","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150535","article-title":"Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma","volume":"132","author":"Kristensen","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0425","doi-asserted-by":"crossref","DOI":"10.1126\/science.288.5466.675","article-title":"Control of homeostasis of CD8+ memory T cells by opposing cytokines","volume":"288","author":"Ku","year":"2000","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690499","article-title":"Cell therapy with TILs: training and taming T cells to fight cancer","volume":"12","author":"Kumar","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.11.014","article-title":"Checkpoint blockade immunotherapy induces dynamic changes in PD-1\u2013CD8+ tumor-infiltrating T cells","volume":"50","author":"Kurtulus","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0440","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.27604","article-title":"Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer","volume":"11","author":"Kverneland","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0445","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003499","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types","volume":"9","author":"Kverneland","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0450","doi-asserted-by":"crossref","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0455","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0460","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.23007","article-title":"Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0465","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001650","article-title":"4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+CD8 T cells from primary and metastatic sites of epithelial ovarian cancers","volume":"8","author":"Leem","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0470","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-019-00523-x","article-title":"Tumor-infiltrating lymphocytes in the checkpoint inhibitor era","volume":"14","author":"Linette","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.09.048","article-title":"Detecting tumor antigen-specific T cells via interaction-dependent fucosyl-biotinylation","volume":"183","author":"Liu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0480","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1202830","article-title":"Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression","volume":"190","author":"Lu","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0485","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-0433","article-title":"Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions","volume":"20","author":"Lu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0490","doi-asserted-by":"crossref","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0495","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s43018-022-00335-8","article-title":"Bystander T cells in cancer immunology and therapy","volume":"3","author":"Meier","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0500","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-15-3352","article-title":"TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T-cell persistence and rejection of established tumors","volume":"76","author":"Menger","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0505","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-2701","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0510","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-0376-4","article-title":"Targeting CD39 in cancer","volume":"20","author":"Moesta","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0515","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.173.2.900","article-title":"IL-21 enhances and sustains CD8 + T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21","volume":"173","author":"Moroz","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00044","article-title":"Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"8","author":"Mullinax","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0525","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1101585","article-title":"Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes","volume":"187","author":"Muralidharan","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0530","article-title":"Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma","volume":"138","author":"Muul","year":"1987","journal-title":"J. Immunol. (Balt. Md. 1950)"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0535","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0110-8","article-title":"Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning","volume":"4","author":"Nelson","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0540","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20142237","article-title":"Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells","volume":"212","author":"Odorizzi","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0545","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.ymthe.2018.08.013","article-title":"Molecular recalibration of PD-1+ antigen-specific T cells from blood and liver","volume":"26","author":"Otano","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0550","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20150304","article-title":"Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance","volume":"212","author":"Palmer","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0555","article-title":"333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program","volume":"8","author":"Palmer","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0560","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0000000000000342","article-title":"Rapid identification and evaluation of neoantigen-reactive T-cell receptors from single cells","volume":"44","author":"Paria","year":"2021","journal-title":"J. Immunother."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0565","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-2680","article-title":"Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression","volume":"23","author":"Parkhurst","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0570","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0b013e31826e8f5f","article-title":"Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma","volume":"35","author":"Pilon-Thomas","year":"2012","journal-title":"J. Immunother."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0575","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2004-06-2482","article-title":"Transition of late-stage effector T cells to CD27+ CD28 + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy","volume":"105","author":"Powell","year":"2005","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0580","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-15-0215","article-title":"Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens","volume":"4","author":"Prickett","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0585","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0590","doi-asserted-by":"crossref","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0595","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.173.12.7125","article-title":"Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy","volume":"173","author":"Robbins","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0600","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0605","doi-asserted-by":"crossref","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T cells by \u03b3c family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0610","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0615","doi-asserted-by":"crossref","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0620","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and Interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0625","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0630","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.11.004","article-title":"Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors","volume":"183","author":"Roudko","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0645","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-020-01218-4","article-title":"The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes","volume":"124","author":"Salas-Benito","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0650","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.10006","article-title":"Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies","volume":"38","author":"Sarnaik","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0655","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0660","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","volume":"25","author":"Scheper","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0665","doi-asserted-by":"crossref","DOI":"10.1038\/80868","article-title":"Interleukin-7 mediates the homeostasis of na\u00efve and memory CD8 T cells in vivo","volume":"1","author":"Schluns","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0670","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.168.10.4827","article-title":"Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells","volume":"168","author":"Schluns","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0675","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-1171","article-title":"Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma","volume":"27","author":"Seitter","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0680","doi-asserted-by":"crossref","DOI":"10.1084\/jem.186.1.47","article-title":"4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses","volume":"186","author":"Shuford","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+ PD-1+ CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0690","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0695","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0700","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00262-016-1917-3","article-title":"5T4 oncofoetal antigen: an attractive target for immune intervention in cancer","volume":"66","author":"Stern","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0705","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0710","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus\u2013associated epithelial cancers","volume":"25","author":"Stevanovic","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0715","article-title":"CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients","volume":"6","author":"Su","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0725","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1988.6.5.839","article-title":"Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study","volume":"6","author":"Topalian","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0815","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20021288","article-title":"Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production","volume":"198","author":"Topp","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0760","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0785","doi-asserted-by":"crossref","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8+ T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0770","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0805","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-019-0697-8","article-title":"Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4","volume":"11","author":"van den Bulk","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0830","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000848","article-title":"Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up","volume":"8","author":"van den Berg","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0735","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0800","doi-asserted-by":"crossref","DOI":"10.1146\/annurev.immunol.23.021704.115839","article-title":"TNF\/TNFR family members in costimulation of T cell responses","volume":"23","author":"Watts","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0750","doi-asserted-by":"crossref","DOI":"10.1038\/cgt.2014.81","article-title":"Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies","volume":"22","author":"Wang","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2020.100332","article-title":"Adoptive transfer of TILs plus anti-PD1 therapy: an alternative combination therapy for treating metastatic osteosarcoma","volume":"25","author":"Wang","year":"2020","journal-title":"J. Bone Oncol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0720","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0730","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0b013e3181b88ffc","article-title":"Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells","volume":"33","author":"Wrzesinski","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0765","doi-asserted-by":"crossref","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0795","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor","volume":"20","author":"Ye","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0850","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8345235","article-title":"TILs and anti-PD1 therapy: an alternative combination therapy for PDL1 negative metastatic cervical cancer","volume":"2020","author":"Yin","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0820","doi-asserted-by":"crossref","DOI":"10.7314\/APJCP.2014.15.1.265","article-title":"Interleukin-7 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells with induction of IFN-gamma in a murine breast cancer model","volume":"15","author":"Yuan","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0780","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0825","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20041057","article-title":"Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function","volume":"201","author":"Zeng","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0835","doi-asserted-by":"crossref","DOI":"10.21873\/anticanres.13689","article-title":"Tissue harvesting for adoptive tumor infiltrating lymphocyte therapy in metastatic melanoma","volume":"39","author":"Zippel","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0740","doi-asserted-by":"crossref","DOI":"10.1038\/nm1312","article-title":"Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+ CD25+ regulatory T cells","volume":"11","author":"Zhang","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0855","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0745","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20062056","article-title":"Induced sensitization of tumor stroma leads to eradication of established cancer by T cells","volume":"204","author":"Zhang","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0755","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.175.10.7046","article-title":"Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy","volume":"175","author":"Zhou","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0790","doi-asserted-by":"crossref","DOI":"10.1097\/00002371-200501000-00007","article-title":"Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy","volume":"28","author":"Zhou","year":"2005","journal-title":"J. Immunother."},{"key":"10.1016\/bs.ircmb.2022.04.003_bb0810","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.173.12.7622","article-title":"Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma","volume":"173","author":"Zhou","year":"2004","journal-title":"J. Immunol."}],"container-title":["International Review of Cell and Molecular Biology","Adoptive Cell Transfer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644822000351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644822000351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T15:14:06Z","timestamp":1753283646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644822000351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323993999"],"references-count":170,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2022.04.003","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}